Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Neuroblastoma Maintenance Therapy Trial

Multiple Cancer Types

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter,
study for patients with neuroblastoma in remission. In this study subjects will receive 730
Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 250 mg/m2 BID (strata 1,
2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on
the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to
prevent recurrence.
Endocrine, Neuroblastoma (Pediatrics), Neuroendocrine, Pediatrics
II
Pastakia, Devang
NCT02679144
VICCPED16157

Improving Care after Inherited Cancer Testing (IMPACT) Study

Miscellaneous

This clinical trial investigates factors associated with access to genetic risk assessment, counseling, and testings services. The trial also seeks to refine and evaluate the effectiveness of online tools on improving cancer risk management practices and family communication of genetic test results.
Miscellaneous
N/A
Pal, Tuya
NCT04763915
VICCSUPP2112

Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel

Multiple Cancer Types

Leukemia, Lymphoma
N/A
Jallouk, Andrew
NCT05776134
VICC-XDCTT23451




Promoting Self-Management in Head and Neck Cancer Survivors with Lymphedema and Fibrosis [PROMISE Trial]

Head/Neck

Head/Neck
N/A
Murphy, Barbara
NCT06125743
VICC-EDHAN23569

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial

Multiple Myeloma

Multiple Myeloma
II
Baljevic, Muhamed
NCT05231629
VICC-ITPCL23014


Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.